Sickle Cell Disease Treatment Demonstration Program | HRSA 21 032

Opportunity Information: Apply for HRSA 21 032

The Sickle Cell Disease Treatment Demonstration Program (TDP) is a federal funding opportunity from the U.S. Department of Health and Human Services (HHS), administered through the Health Resources and Services Administration (HRSA). Released on February 23, 2021, under Funding Opportunity Number HRSA 21 032 and CFDA 93.365, the program is offered as a discretionary cooperative agreement. In practical terms, that means awardees would not only receive funding but would also work closely with HRSA in carrying out the project, typically with ongoing federal involvement in areas like program guidance, performance expectations, and reporting.

The overall goal of the TDP is to expand access to high-quality, coordinated, and comprehensive care for people living with sickle cell disease (SCD). The opportunity is centered on three connected outcomes. First, it aims to increase the number of clinicians and other health professionals who are knowledgeable about SCD care, which can include improving clinical confidence, spreading evidence-based practices, and strengthening the workforce capacity to manage both routine and complex SCD needs. Second, it focuses on improving the quality of care delivered to individuals with SCD, suggesting an emphasis on better clinical practices, more consistent standards of care, and measurable improvements in patient outcomes and patient experience. Third, it seeks to improve care coordination with other providers, reflecting the reality that SCD management often requires teamwork across primary care, hematology, emergency departments, pain management, behavioral health, social services, and other specialties to reduce gaps, duplication, and preventable complications.

HRSA anticipated making about five awards under this announcement. The listing shows an award ceiling of 0, which typically signals that the maximum award amount was not specified in the summary field and would need to be confirmed in the full funding notice or related application guidance. The application deadline for the original closing date was May 3, 2021. Eligibility is labeled broadly as "Others," with the note that applicants should consult the additional eligibility details in the full announcement for clarification, implying that eligible organizations may extend beyond a single standard category and could include various types of entities depending on the program rules.

In short, this program is designed to strengthen the SCD care system by building provider expertise, raising the quality of clinical services, and tightening coordination across the healthcare network so that people with sickle cell disease can more reliably access comprehensive, well-organized care.

• The Department of Health and Human Services, Health Resources and Services Administration in the health sector is offering a public funding opportunity titled "Sickle Cell Disease Treatment Demonstration Program" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.365.
• This funding opportunity was created on Feb 23, 2021.
• Applicants must submit their applications by May 03, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for HRSA 21 032

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: